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Porcine circovirus type 2 (PCV2) has been a major problem for the pig production industry 
worldwide for decades. While the majority of commercially available vaccines are based 
on the original PCV2a genotype, the current dominant genotype is PCV2d. The notable 
differences between genotypes could lead to incomplete cross-protection. Moreover, most 
current subunit PCV2 vaccines are generated from expensive insect cell culture 
technology. In this work, we present a new workflow for production of an updated and 
relatively inexpensive PCV2d vaccine candidate. After expression in fed-batch Escherichia 
coli fermentation systems with a simple one-step ion-exchange chromatography 
purification protocol, the yield of purified PCV2d-based antigen reached over 1 g per litre 
bacterial culture. Using similar procedures, we also demonstrated even higher PCV2d-
based antigen yields from a chimeric PCV2d-PCV3 capsid construct, which is cleaved 
during fermentation to release PCV2d- and PCV3-related polypeptides. Although the 
PCV2d-based recombinant protein from this protocol did not form viral-like particles as 
analysed by size-exclusion chromatography, it could effectively induce capsid-specific and 
PCV2d-neutralising antibodies in immunised animals, indicating significant potential as a 
new vaccine candidate that can be easily manufactured at commercial scale.  
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Porcine circovirus-associated disease (PCVAD) has been a massive problem for the swine 
industry worldwide, producing a range of symptoms such as weight loss, enlarged lymph 
nodes, jaundice, respiratory distress, diarrhea and reproductive failure in infected herds 
(reviewed in [1-3]). Importantly, PCVAD weakens the pigs’ immune systems, leading to 
severe secondary infections by other pathogens. Its etiological agent, porcine circovirus 
type 2 (PCV2), is a small non-enveloped virus, comprising only 60 copies of capsid protein 
monomers [1,4]. The viral genome contains two main open reading frames (ORFs). ORF1 
encodes the protein ‘rep’ which functions in viral replication. ORF2 encodes the protein 
‘cap’ which makes up the only structural component of the virus [1]. Despite being a DNA 
virus, PCV2 exhibits remarkably high evolutionary rates (1.2 x 10-3 substitutions per site 
per year; [5]). To date, there are six genotypes of PCV2: PCV2a, PCV2b, PCV2d (high 
prevalence history) and PCV2c, PCV2e, PCV2f (low prevalence history) [6,7]. Even 
though PCV2a-based vaccines were introduced in the early 2000s and used widely since, 
PCV2 is still endemic in many parts of the world and remains a major threat in swine 
farms.  
 
In 2016, another related virus, designated porcine circovirus type 3 (PCV3), was 
discovered in pigs with porcine dermatitis and nephropathy syndrome, reproductive failure 
and cardiac and multi-systemic inflammation [8]. Etiological proof was demonstrated later 
when intranasal infection with laboratory-derived PCV3 induced clinical signs in specific-
pathogen-free piglets [9]. Serological surveys demonstrated widespread presence of 
PCV3 in pig farms in many areas of the world (e.g. [10]. Currently, there is no commercial 




To date, most commercial PCV2 vaccines are based on the capsid protein derived from 
the first genotype discovered, PCV2a [11]. Longitudinal epidemiological data indicate that 
PCV2a has been replaced by PCV2b and later PCV2d, currently the most prevalent strain 
worldwide [12]. Several studies have suggested that PCV2a-based vaccines could give 
some, albeit incomplete, cross-protection to other genotypes, as pigs vaccinated by one 
genotype but challenged by another showed reduced viral load, but could still shed the 
viruses [6,13,14]. Importantly, in co-infection experiments mimicking farm conditions, a 
PCV2a-based vaccine was less effective than a PCV2b-based vaccine in protecting pigs 
against PCV2b concurrent infections with other swine pathogens [15]. Even more distant 
from PCV2a, PCV2d may have arisen from vaccine evasion, as it was identified as a 
PCV2b variant from vaccine failure cases in PCV2a-vaccinated herds [16]. Therefore, 
updating PCV2 vaccines to address the changing threat is crucial.  
 
Another major concern is that commercial PCV2 vaccines can be too expensive, imposing 
large burdens on farmers and creating an inequitable access problem. To reduce 
production cost for recombinant subunit vaccines, microbial fermentation is an attractive 
choice. In this report, we present a new workflow for production of a PCV2d subunit 
vaccine candidate. With industrial-scale feasibility in mind, we generated recombinant 
PCV2d capsid proteins from E. coli expression, streamlined the tag-independent 
purification process to achieve a substantial yield of 1 g protein/L starting culture, and 
assessed the quality of the product with an industrial standard method of mass 
spectrometry.The resulting protein was capable of inducing neutralising antibodies in test 
animals, suggesting its potential as a vaccine. We also tested a chimeric protein consisting 
of antigens from PCV2d and PCV3 capsid proteins. Interestingly, the chimera is almost 
quantitatively cleaved in the linker sequence to release high quantities of PCV2d and 
measurable levels of PCV3. The levels of PCV2d are even higher than those obtained 
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during expression of PCV2d on its own, demonstrating that the chimeric construct 
represents a novel method to produce a PCV2d vaccine candidate. Moreover, the 
presence of peptides derived from PCV3 capsid proteins suggests that this process can 
also be adapted to produce PCV3 vaccines.       
 
2. Materials and Methods 
 
2.1. Bacterial strains and plasmids 
E. coli strains and plasmids used in this work are detailed in Table 1. BL21 and W3110 
were used for shake flask level expression experiments and W3110 was used for 
fermentation experiments.  
 




DH5α E. coli K-12 strain. F– φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 
hsdR17(rK–, mK+) phoA supE44 λ– thi-1 gyrA96 relA1 
ThermoFisher 
BL21 E. coli B strain. F– ompT gal dcm lon hsdSB(rB–mB–) [malB+]K-12(λS) ATCC 
W3110 E. coli K-12 strain. F- λ- rph-1 INV(rrnD, rrnE) ATCC 
pARP25 pET23/ptac Δ2-40 PCV2d-His6 This study 
pARP30 pET23/ptac Δ2-40 PCV2d-GSGSG-Δ2-34, Δ195-214 PCV3-His6 This study 
pARP31 pET23/ptac Δ2-40 PCV2d-GSGSG-Δ1-34, Δ195-214 PCV3-His6 This study 
pARP34 pET23/ptac Δ2-40 PCV2d-GGGGS-Δ1-34, Δ195-214 PCV3-His6 This study 
pARP35 pET23/ptac Δ2-40 PCV2d-EAAAK-Δ1-34, Δ195-214 PCV3-His6 This study 
pARP36 pET23/ptac Δ2-40 PCV2d-AEAAAKALEAEAAAKA-Δ1-34, Δ195-214 PCV3-H6 This study 
pARP37 pET23/ptac Δ2-40 PCV2d-EPEPEP-Δ1-34, Δ195-214 PCV3-His6 This study 
pARP38 pET23/ptac Δ2-40 PCV2d - Δ1-34, Δ195-214 PCV3-His6 This study 
Table 1. Strains and plasmids used in this work. 
 
The PCV2d ORF2 and PCV3 ORF2 coding sequences were optimised for bacterial 
expression based on the published amino acid sequences of Porcine circovirus 2 isolate 
NPT135 capsid protein (MF314329) and Porcine circovirus 3 isolate PCV3-China/GD2016 
(KY418606.2), respectively. Full length genes were cloned into a modified pET23a 
expression vector with ptac promoter system by restriction cloning. A construct was made 
containing PCV2d gene only, and another chimeric construct was made containing both 
PCV2d and PCV3 capsid genes joined by a short GSGSG linker region. Truncations were 
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made to the genes by PCR amplification using 5’ phosphorylated primers and direct 
ligation. The PCV2d N-terminal NLS region consisting of amino acids 2-40 was truncated 
in both single PCV2d and chimeric PCV2d-PCV3 constructs. The PCV3 putative N-
terminal NLS region consisting amino acids 2-34 was truncated in both chimeric PCV2d-
PCV3 constructs, pARP30 and pARP31, using forward primer 19_ΔNLS_PCV3_F (5’ P- 
GCAGGCACCTATTATACCAAAAAATACA 3’) and reverse primer 
20_Chimera_ΔNLS_PCV3_R (5’ P-CATACCACTACCGCTACCTTTCGGA 3’). An 
additional truncation of amino acids 195-214 in the PCV3 C-terminal region of the chimeric 
PCV2d-PCV3 construct was made using forward primer 23_PCV3_HIS_F (5’ P-
CATCATCACCACCATCACTAAAC 3’) and reverse primer 22_PCV3_C-term_R (5’ P-
GGTTTTTTCCGGAACATAAATTG 3’). Constructs pARP34 to pARP38 contain linker 
sequences with varying amino acid compositions and were made from pARP31 construct, 
also PCR amplified using 5’phosphorylated primers, using the same reverse primer 
36_pARP31Linker_R (5’ P-TTTCGGATTCAGAGGCG 3’) and individual forward primers 
containing the sequence to be replaced (Table 2). 
 
Plasmid Forward primer name Forward primer sequence 
pARP34 37_Linker_overlap_F  5’ P-GGTGGTGGTGGTTCTGCAGGCACCTATTATACCA 3’ 







pARP37 40_Linker_overlap_F 5’ P-GAACCGGAACCGGAACCGGCAGGCACCTATTATACCA 3’ 
pARP38 41_NoLinker_F 5’ P-GCAGGCACCTATTATACCA 3’ 
Table 2. Forward primers used to generate chimeric PCV2d-PCV3 constructs with 
alternate linker regions. 
 
2.2. Shake flask cell culture 
Shake flask expression of recombinant proteins was initiated in 50 mL LB medium 
containing 100 µg/mL ampicillin by inoculation with the overnight pre-inoculant culture to 
an optical density (OD600) of 0.05. The culture was grown at 30 °C, 200 rpm for 
approximately 3 hours until the OD600 of the culture reached 0.4-0.6. Once reached, 
expression was induced by addition of 100 µM IPTG. Cell samples were harvested at 3 
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hours and 21 hours after induction. At the specified timepoints, the OD600 of the culture 
was determined and a volume of culture equivalent to 10 OD600 was harvested by 
centrifugation at 3000 rpm for 10 minutes at 4 °C. The cell pellet was resuspended in 1 mL 
resuspension buffer (50mM Tris-acetate, 2.5 mM EDTA, pH 7.0) then lysed by sonication 
in ice at all times, using amplitude 8.0 (Soniprep 150plus, Sanyo Gallenkamp, 
Loughborough, UK) for 4-6 rounds (10 s on/10 s off). Lysed suspensions were centrifuged 
at 14,000 rpm for 15 minutes at 4 °C and the supernatant kept as “Soluble” cell fraction, 
while the pellet was resuspended in a further 1 mL resuspension buffer and kept as 
“Insoluble” cell fraction, for analysis by SDS PAGE. 
 
2.3. Fed-batch fermentation 
A pre-inoculant culture was prepared by inoculating a single transformed W3110 E. coli 
colony into 5 mL TB media with antibiotic and grown for 6-8 hours 37 °C, 250 rpm. One 
mL of the pre-inoculant was transferred to a 1 L baffled flask containing 200 mL SM6Gc 
media with antibiotic and grown overnight at 30 °C, 250 rpm. The next day, 300 OD600/L of 
the overnight culture were inoculated into SM6Gc medium into an Infors Multifors 1.5 L 
fermenter (Infors UK Ltd., Reigate, UK), to a total volume of 500 mL. To this, 100 µg/mL 
ampicillin and 1 mL/L PPG 2000 were added. The pH was maintained at 7.0 using 25% 
(v/v) ammonia solution and 25% (v/v) sulphuric acid. Dissolved oxygen tension was 
regulated at 40% using gas blending with 100% oxygen. The culture was grown at 30 °C 
until both stirrer and airflow was maximal, then the growth temperature was lowered to 25 
°C. Once the culture had reached OD600 38-42, a supplement of 8 mL/L 1 M MgSO4•7H2O 
was added. At OD600 54-58, 5 mL/L 1.687 M NaH2PO4 was supplemented. At OD600 60-
65,  7 mL/L 1.687 M NaH2PO4 was supplemented, a glycerol feed (80 % (w/v) glycerol) 
was set at a rate of 0.025 mL/min, and protein expression was induced by adding 9 mL/L 
0.0181 M IPTG. At the end of the experiment, the 500 mL culture was harvested by 
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centrifugation in 250 mL bottles at 4000 rpm for 40 minutes at 4 °C. Cell pellets were 
stored at -20 °C until use. For processing, the cell pellets were resuspended in 
resuspension buffer (15 % w/v) and lysed using a Gaulin style homogeniser at 500 bar for 
4 passages. Lysates were centrifuged at 15,000 rpm for 30 minutes at 4 °C. The 
supernatant containing soluble proteins was aspirated and taken forward for purification. 
 
2.4. Cation exchange purification  
Soluble cell lysates were purified by HPLC with a single step of cation exchange 
chromatography using a pre-packed HiTrap™ SP Sepharose HP 5 mL column (GE 
Healthcare, Buckinghamshire, UK), in an AKTA Pure refrigerated system, under reducing 
conditions using DTT unless otherwise specified. The column was loaded with the soluble 
cell lysate (with 0.1 mM DTT added) and washed with Binding buffer (50 mM Tris-HCl, 0.1 
mM DTT, pH 7.0). Then, an elution gradient was applied in stepwise increments of 50 mM 
increasing salt concentration over 20 CV, using a combination of Binding buffer and 
Elution buffer (50 mM Tris-HCl, 1 M NaCl, 0.1 mM DTT, pH 7.0). Eluted samples were 
analysed by SDS PAGE and the protein content was determined by Bradford Assay. 
 
2.5. Gel filtration chromatography 
Gel filtration chromatography was carried out using Superdex™ 200 Increase 10/300 GL 
column (GE LifeSciences) in a refrigerated AKTA Pure system. The column was washed 
with 2 CV filtered and degassed water at flow rate 0.4 mL/min, then equilibrated with 2 CV 
Gel filtration buffer (50 mM sodium phosphate, 100 mM NaCl, pH 7.0) at flow rate 0.5 
mL/min. Protein samples used had been previously purified by cation exchange without 
DTT. Samples with concentrations between 0.25-0.5 mg/mL (500 µL) were centrifuged at 
60,000 rpm for 20 minutes, 4 °C to pellet any insoluble material prior to loading onto the 
column through a 1 mL capillary loop. Gel filtration buffer was run through the column (flow 
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rate 0.5 mL/min) until no more protein peaks were observed on the UV trace. Elutions 
were collected in 1 mL fractions. Their molecular weights were determined using a 
calibration curve created with GE Healthcare Gel Filtration Calibration HMW and LMW 
kits, according to manufacturer's protocol. 
 
2.6. Sample processing for mass spectrometry 
Samples were dialysed (Thermo Fisher Scientific, Slide-A- Lyzer 3.5K MWCO Dialysis 
Cassettes 0.1-0.5 mL) against PBS (tablets Gibco). The samples were resuspended in 
water, and a BCA assay (Thermo Fisher Scientific) was carried out to determine protein 
concentration. Finally, aliquots of 10 µg or 20 µg, respectively, were vacuum concentrated 
to dryness prior to further downstream processing.  In-solution trypsin digestion: protein 
denaturation and reduction of disulfide bonds were achieved by adding 10 µL of 8 M 
guanidine-HCl solution (Thermo Fisher Scientific) to the PCV2d sample (10 µg or 20 µg) 
followed by 1 µL of 10 mM DTT (Thermo Fisher Scientific) in 50 mM ammonium 
bicarbonate buffer (Sigma) at pH 8.4. The solution was incubated for 30 min at 56 °C. 
Next, carboxymethylation of the free sulfhydryl groups in PCV2d was achieved by adding 
of 1 µL 55 mM iodoacetamide (Thermo Fisher Scientific) in 50 mM ammonium bicarbonate 
buffer at pH 8.4 followed by an incubation for 30 min at room temperature in the dark. For 
the results in the pilot study, we used iodoacetic acid (Sigma) instead of iodoacetamide. 
The reaction was diluted to 30 µl using ammonium bicarbonate buffer (pH 8.4). For the 
protein digestion, modified trypsin (porcine, sequencing grade from Promega) was added 
to the PCV2d in a ratio of 1 in 20 (trypsin:protein). The digestion was incubated at 37 °C 
for 12 hours. The digestion was stopped by adding trifluoroacetic acid (ROMIL, analytical 
grade) to a final concentration of 0.5% (v/v). 
 
2.7. LC-MS/MS Analysis 
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For sample analysis, online ESI-LC-MS was used on a nanoAcquity UPLC®-system and 
Waters Synapt® G2-S mass spectrometer. For sample trapping, an Acquity UPLC® M-
Class Trap V/M Symmetrie® C18 (1.8 µm 75 µm x 150 mm) was applied. Higher 
resolution of the sample components was achieved by inserting an Acquity UPLC® M-
Class column (HSS T3 1.8 µm 75 µm x 150 mm) equilibrated at 40 °C. The mobile phases 
was A: 0.1% (v/v) formic acid (Biosolve Chemicals) in 1 L LC-MS grade water (Greyhound) 
and B: 0.1% (v/v) formic acid (Biosolve Chemicals) in 1 L acetonitrile (Greyhound). 
Lockmass was set to m/z: 785.80 Glu-1-Fibrinopeptide B (200 nmol/µL, Waters).  
 
For individual sample runs, the Synapt G2-S mass range was operated between 50-2000 
m/z. Electrospray inlet parameters were set to a source temperature 80 °C and a capillary 
voltage at 2.4 kV. The resolution mode (20,000 FWHM) was recorded as a continuum 
MS/MS data format with a collision energy ramp from 14 to 45 eV and an intensity 
threshold above 2000 for triggering MS/MS measurements. MS/MS recording was 
switched off after 10/5 sec. Sample injection volume of 1 µL (200 fmol) was loaded for 2 
min with a flow rate of 0.5 µL /min. Trapping was carried out for 5 min with a solvent 
mixture of 99.9% solvent A and 0.1% solvent B under a flow rate of 5 µL/min. For online 
sample separation, a linear gradient was chosen for 45 min ranging from 5% to 60% 
solvent B mixed with the required amounts of solvent A, respectively. A column wash was 
achieved by an initial equilibration of 97% solvent A and 3% solvent B, followed by a linear 
increase in solvent B to 97% (+solvent A 3%) for 5.5 min. The final equilibration period 
was scheduled for about 10 min with 97% solvent A and 3% solvent B. The system was 
operated at a constant flow rate of 0.3 µL/min at all times during the linear gradient. As 
reference mass Glu-1-Fibrinopeptide B (m/z: 785.8) was added.  
 
2.8. Peptide mapping 
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The generated raw file data (Waters) were analysed using the BioPharmaLynx 1.3.3 and 
the MassLynx V4.1 software. For automated peptide mapping analysis with 
BioPharmaLynx, the following parameters were considered: lock mass correction with 
785.85 and 0.25 Da mass tolerance during MSE data processing. Additionally, two missed 
cleavages, trypsin digestion and carbamidomethyl as fixed Cys modification. To improve 
sequence coverage, we allowed one methionine oxidation as a variable modification. 
Mass tolerance was set to 30 ppm. Mass errors observed were quite low with 3 ppm for 
Figure 3 and below 20 ppm for fraction 8 and 10 (see data in Figure 6).  Background 
exclusion was based on manual signal evaluation via MassLynxV4.1 with local signal 
noise ratios of 1:10 threshold. This should exceed 0.01% of maximum total intensity 
current at all times. Intensity signals below 10 were excluded from the mapping. Protein 
database searches were carried out with PLGS software (Waters). The data raw file was 
loaded into a cap plate and rerun against the general UniProt database or general Swiss-
Prot database. Search parameters were set to one missed cleavage, one oxidation as 
variable modification for methionine and one fixed variable carboxymethyl or 
carboxyamidomethyl for cysteine. Host cell proteome contamination was tested against 
the general Swiss-Prot E. coli database.  
 
2.9. Immunofluorescence assay 
PCV2d infectious virus was generated by transfection of PCV2d (strain BDH) genomic 
concatemers (accession number HM038017; [17]) into PCV-free PK-15 cells. 
Immunofluorescence assay (IFA): PCV-free PK-15 cells were plated to about 80 % 
confluence in a cover slide. On the next day, PCV2d (strain BDH) was incubated with the 
cells for 3 h at 37 °C. Following removal of the PCV2d inoculum, the cells were incubated 
in fresh MEM with 5% FBS at 37 °C for 72 h. Anti-PCV2d capsid antibody, produced in this 
study, was used as a primary antibody at the 1:1000 dilution in TBS+0.01% tween-20. 
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Alexa488-labeled goat-anti-rabbit IgG was used as a secondary antibody, and DAPI was 
used to identify cell nuclei. Fluorescence images were taken using an Olympus 
fluorescence microscope. 
 
2.10. PCV2d virus neutralisation assay 
Neutralisation assay based on fluorescent foci reduction was performed according to [18] 
with some modifications. Briefly, 50 µL of 2-fold serial dilutions of rabbit antisera (Bleed 3) 
in MEM were incubated with 50 µL containing 1000 PCV2d particles at 37 °C for 1 h. The 
undiluted pre-immunisation sera were used as a control. After incubation, the mixtures 
were used to inoculate fresh PK-15 cells in a 96-well plate (15,000 cells/well) at 37 °C for 3 
h. After two PBS washes, 200 µL of MEM supplemented with 5% fetal bovine serum (FBS) 
was added to each well, and the plate was incubated at 37 °C for 48 h. PCV2d infection 
was later detected by immunofluorescence. After two PBS washes, cells were fixed with 
80% acetone for 15 minutes at room temperatures. With PBS washes in between, rabbit-
anti-PCV2d capsid antibody was used as a primary antibody and Alexa488-labeled goat-
anti-rabbit IgG was used as a secondary antibody. DAPI was used to identify cell nuclei, 
and the numbers of infected cells (concurrence of DAPI- and Alexa488-positive nuclei) 
were scored on a high-content screening system (Opera Phenix). Virus neutralisation titres 
(VNT) were defined as the serum dilutions at which 50% inhibition of PCV2d infection 










3.1. Design of PCV2d and PCV2d-PCV3 capsid protein constructs and expression in E. 
coli 
 
The sequence of the protein was chosen on the basis of sequence data from PCV2 strains 
that are prevalent in South East Asia [19], and Figure 1 shows the protein constructs 
chosen for this study. This PCV2d capsid protein sequence (hereafter termed PCV2d) 
contained deletions of the N-terminal 2-40 amino acid residues as previous studies 
suggested that multiple arginines in this region interfere with protein expression in bacteria 
[20-22]. We also expressed a chimeric construct comprising the PCV2d capsid protein 
sequence described above linked to a portion of PCV3 capsid protein via a short linker as 
shown in Figure 1. This chimeric sequence is hereafter termed PCV2d-PCV3 (amino acid 
sequences of both constructs are shown in Figure 6). 
 
The sequences were cloned into the pET23a/ptac vector and expressed in E. coli W3110 
cells grown in shake flask cultures.  Expression was induced with IPTG for 3 h. Analysis of 
the Coomassie-stained gel shows the presence of an abundant 25 kDa band which was 
confirmed to be PCV2d by immunoblotting (Figure 2). The protein is found mostly in the 
soluble fraction. Expression of the PCV2d-PCV3 chimera results in the presence of an 
abundant 43 kDa band which is found primarily in the insoluble fraction, probably as 
inclusion bodies (Figure 2, left). However, it is notable that a significant amount of soluble 
PCV2d protein is present in the soluble fraction, suggesting that the chimeric construct is 
partially cleaved within the linker region to yield PCV2d. 
 




In order to purify PCV2d in large quantities in preparation for industrial process adaptation, 
we cultured cells under fed-batch fermentation conditions for an extended period. 
Induction of PCV2d was carried out using IPTG and the cells were harvested 42 h after 
induction. Although the construct contains a His tag, we opted for ion exchange (IEX) 
chromatography as this tag-independent method is more suitable for industrial-scale 
production. Once developed, the purification protocol could be transferred for a non-tag 
version with minimal changes. The cells were lysed, centrifuged and the supernatant was 
subjected to the HiTrap™ SP Sepharose FF column. The column was washed as detailed 
in Methods, and the PCV2d protein was eluted using a 0 - 1 M NaCl gradient. 
 
Figure 3A shows a Coomassie-stained gel of the elution fractions. The PCV2d construct 
has a pI of 9.4 and at the pH used (7.0) the vast majority of the native E. coli proteins pass 
through the column without binding (not shown). The Figure shows that the later wash 
fractions contain relatively few proteins and the PCV2d protein elutes in large quantities 
late in the NaCl gradient (at an NaCl concentration of approximately 700 mM). The protein 
runs as a close doublet of bands on SDS-PAGE. A sample of the peak fraction was 
analysed by proteomic analysis. The base peak intensity chromatogram after 200 fmol 
injection is shown in Figure 3B. Peptide mapping of PCV2d from the resulting dataset 
yielded a protein sequence coverage of 95%. Most ions could be identified successfully 
via MS/MS fragmentation with a very low mass error +/- 3 ppm (Figure 3C). The PAGE 
also showed a band at 25 kDa which was established as a His-tag cleavage product 
(Supplementary Figure 1). Database search against the general Uniprot database resulted 
in a single hit for the capsid protein of the porcine circovirus 2 (accession: O56129, entry: 
CAPSD_PCV2) with a PLGS score of 5642.6. The mass spectrometry data here support 
that this single-step chromatography protocol is ideal for the production of PCV2d in large 




3.3. Production of a combination of soluble PCV2d and PCV3 using a chimeric construct 
 
The chimeric PCV2d-PCV3 construct was designed with the aim of producing a 
combination of PCV2d and PCV3 for vaccine purposes, and we showed above that this 
construct expresses in high amounts in E. coli, but is insoluble when produced in shake 
flask cultures. However, we observed that some PCV2d, possibly cleaved from the 
chimera during expression, is present in the soluble fraction (Figure 2, right). These results 
suggest that this process, involving expression of the PCV2d-PCV3 construct, is a 
potential method of producing large amounts of PCV2d, and we further tested different 
cultivation conditions in order to assess whether yields could be enhanced. 
 
Figure 4 shows a time course analysis of shake flask cultures grown in fermentation media 
of cultures expressing PCV2d alone or PCV2d-PCV3. Cells were removed after 3, 5 and 
21 h and separated into soluble and insoluble fractions. These were then immunoblotted 
using antibodies to PCV2d. The data show that PCV2d is present in all of the samples and 
present in both the soluble and insoluble fractions. The data from the PCV2d-PCV3 culture 
show that this protein is also present at all of the timepoints, and the intact chimera is 
again found mostly in the insoluble fraction. However, the unexpected finding is that under 
these more prolonged expression conditions the vast majority of protein is cleaved and the 
blot shows the presence of large quantities of soluble PCV2d. The protein is present as a 
mix of closely grouped protein species with the most abundant being approximately the 
same size as PCV2d that is expressed on its own. These data indicate that the chimera is 
efficiently cleaved within the linker peptide to yield a series of PCV2d isoforms that differ 
by only a few amino acids. The combined intensities of these bands are even greater than 
those of the PCV2d proteins after expression of PCV2d on its own, and these results 
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indicate that this process, involving expression of the PCV2d-PCV3 construct, is a viable 
method of producing particularly large amounts of PCV2d. 
 
To confirm this point, we carried out a full fed-batch fermentation analysis similar to that 
used for PCV2d on its own (above). The data in Figure 5 show that the chimera is 
efficiently cleaved to yield soluble PCV2d throughout a full 42 h induction period; the 
soluble PCV2d protein is by far the most abundant protein at all time points in the PCV2d 
immunoblot. We then subjected the soluble fraction from the 42 h time point to ion 
exchange chromatography and a Coomassie-stained gel of the eluate is shown in Figure 
6A. Once again, the vast majority of the native E. coli proteins do not bind to the column 
under these conditions and are found in the flow-through (FT) or wash fractions. The 
PCV2d elutes in a relatively pure form at a late point in the NaCl gradient. The fractions 
contain several lower molecular weight proteins, some of which are PCV2d or PCV3-
related (see below). 
 
To assess the overall efficiency of the expression/purification process we pooled peak 
fractions containing the PCV2d alone (as in Figure 3A) and determined the concentration 
of the protein. This gave us an overall figure of 1 g protein per litre of fed-batch culture. 
Similar analyses of the PCV2d derived from the PCV2d-PCV3 chimera gave a slightly 
higher figure, but the absence of a PCV3-specific antiserum means that we are not able to 
determine the concentration of PCV3 with accuracy. In order to determine whether PCV3 
is indeed present, we analysed the IEX peak fractions 8 and 10 containing PCV2d-PCV3 
using online ESI-LC-MS as mentioned above. The samples were injected as estimated 
500 fmol/ µL and the corresponding base peak intensity chromatograms are shown in 
Figure 6B. The Coomassie stained protein bands of the earlier fraction 8 suggest the 
presence of higher background proteome compared to the later fraction 10, which appears 
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to be more enriched in PCV2d and possibly PCV2d-PCV3 protein. Interestingly, the 
peptide mapping analysis for each IEX fraction indicated a nearly complete coverage of 
the PCV2d protein region including an intact GSGSG linker sequence. This finding was 
supported by a strong MS/MS fragmentation of the individual peptides derived from the 
PCV2d region. However, characterisation of the PCV3 protein region was more 
challenging. The only identified peptide signals specific for PCV3 were present at low to 
very low signal-to-noise ratios (Supplementary tables 1&2- only SN>5 shown). Low 
intensities may correspond to signal suppression or lower quantities of PCV3 within the 
sample. In addition, the total sequence coverage for PCV2d-PCV3 reached similar 
percentages for both IEX fractions with 61.1% (fraction 8) and 57.9% (fraction 10), 
respectively (Figure 6C).  
 
Based on our earlier findings and the proteomic dataset we concluded again that the 
chimeric PCV2d-PCV3 protein might have been accumulated in inclusion bodies after 
expression and could not be reliably identified in the supernatant and that it is also subject 
to proteolytic degradation. However, this construct could produce large amounts of high-
purity PCV2d possibly supplemented with some detectable PCV3-derived peptides.  
 
3.4. Purified PCV2d is not in the form of a virus-like particle (VLP).  
 
Several previous studies showed that purified recombinant PCV2 can form large VLPs that 
resembles the intact virus in terms of overall dimensions [23-25]. We considered it 
important to understand whether our preparations behave in this manner and therefore 
subjected them to calibrated size-exclusion chromatography using a Superdex 200 
column. This column separates molecules within the range of 10 kDa to 600 kDa; larger 
molecules elute earliest of all in the void volume. The column was calibrated with 
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molecular weight markers and the insert in Figure 7 shows that the markers are effectively 
separated, with the largest protein marker (669 kDa) having a column retention volume of 
approximately 9.6 ml. Figure 7 also shows an immunoblot of the elution characteristics of 
the PCV2d derived from cleavage of the PCV2d-PCV3 chimera; the data show that peak 
elution is observed with a retention volume of 17 ml; this is similar to that of the 29 kDa 
size marker. Very similar data were obtained with PCV2d that was expressed on its own 
(not shown) and these results thus show that purified PCV2d is not in the form of a VLP. 
Most likely, it is either monomeric or dimeric; the size exclusion results cannot distinguish 
between these possibilities because retention volume is not totally dependent on protein 
mass.  
 
3.5. Production of antisera to PCV2d 
 
Previous studies have suggested the importance of VLP formation for efficient PCV2 
recombinant subunit vaccines. Since our protein construct does not seem to form VLP, we 
tested its immunogenicity in animals. Two different rabbits were immunised with purified 
PCV2d and the effectiveness of the antisera is shown in Figure 8A, which shows blots 
obtained with antisera from rabbits 1 and 2. Preliminary experiments confirmed that the 
pre-immune sera show no reactivity to PCV2d (not shown).  
 
Figure 8A shows that antisera from both animals specifically recognise the PCV2d protein 
in a lysate of E. coli cells expressing PCV2d, with no evidence of cross-reactivity to other 
E. coli proteins. The antisera also detected PCV2d when diluted 1/5. The antisera 
furthermore detected the PCV2d-PCV3 chimera in a lysate from cells expressing this 
construct. A range of lower molecular mass peptides are also detected, which is clear 
evidence that the chimeric protein is cleaved to a series of smaller PCV2d- and PCV3-
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related peptides. This observation is consistent with the observation that multiple bands 
are apparent below the soluble PCV2d protein that is produced during fed-batch 
fermentation of PCV2d-PCV3 (Figure 6A). As controls we ran purified PCV3 protein and a 
lysate of E. coli cells expressing a single chain variable antibody fragment (scFv) and no 
cross-reaction is observed in either case. This confirms that antisera from both rabbits 
specifically recognise PCV2d but not PCV3. 
 
We further tested the antisera for the ability to recognise PCV2d capsid protein produced 
during PCV2d infection. PK-15 cells, which are susceptible to PCV2 infection, were mock-
infected or infected with PCV2d (strain BDH). At 48 h post-infection, infected cells were 
stained with anti-PCV2d purified from the rabbit antisera as a primary antibody. As shown 
in Figure 8B, cells infected by PCV2d could be clearly labelled with anti-PCV2d antibody 
while those mock-infected showed a very clean background. These results demonstrate 
that anti-PCV2d antibody, generated by immunisation with our recombinant protein, could 
recognise the native structure of the PCV2d capsid protein produced during viral infection 
in swine cells.    
 
3.6. The antisera can neutralise PCV2d infection in cell-based assay.  
 
We finally addressed the key question of whether the antibodies raised in immunised 
animals have virus neutralising properties. A preparation of PCV2d virus was incubated 
with serial dilutions of antisera from each rabbit as indicated in Methods prior to infection in 
PK-15 cells. As a negative control, the viruses were incubated with undiluted pre-
immunisation sera. PCV2d infection was detected by immunofluorescence using rabbit 
anti-PCV2d capsid antibody as the primary antibody and Alexa-488-labeled goat-anti-
rabbit IgG as the secondary antibody. Representative figures showed significant reduction 
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of infected cells up to 1:16 sera dilution compared to the conditions in which the virus was 
pre-incubated with the pre-immunisation sera (Figure 9A). Quantitative analysis on the 
Opera Phenix high-content screening system demonstrated the dose-dependent 
neutralising activity for both rabbits, and gave the virus-neutralising (VN) titres of 28±7 for 
Rabbit 1 and 19±2 for Rabbit 2, while the VN titres for pre-immunisation sera were 
negligible (Figure 9B). The data in this section indicate that PCV2d antigen produced in 
our system can induce virus neutralising antibodies in test animals and suggest its 
potential use as a subunit vaccine. 
 
 
4  Discussion 
 
The introduction and subsequent wide adoption of PCV2a-based vaccines helped to 
significantly mitigate losses due to severe PCVAD symptoms in vaccinated farms. 
However, the emergence and perpetuation of new genotypes such as PCV2b and PCV2d 
could be viewed as evidence for a “leaky vaccine” situation, wherein the widespread 
vaccination could reduce clinical signs but could not eradicate transmission and therefore 
influenced evolution of heterologous viral strains [6,11]. PCV2d capsid proteins differ from 
those of PCV2a by 23 amino acids (out of 233/234 amino acids), including several 
mutations in internal epitopes and an insertion at the neutralising C-terminal epitope 
(reviewed in [6]). Several experiments have suggested that homologous vaccination would 
be more effective than heterologous vaccination for the case of PCV2. Therefore, updates 
in PCV2 vaccines to match currently circulating strains are highly desirable. Moreover, if 
the vaccines need regular updates, the development of more cost-effective and adaptable 
production platforms such as microbial fermentation can be highly beneficial for 




The PCV2d antigen production protocols in this study offer significant potential for further 
development into a competitive commercial PCV2 vaccine. First, the E. coli fermentation 
platform coupled with a single-step chromatographic protocol generated particularly high 
yields: over 1 g purified protein per litre starting bacterial culture. This range of yield has 
not been reported in previous work on microbial fermentation of PCV2 capsid proteins. For 
comparison, VLP production from a similar PCV2 capsid protein construct lacking the N-
terminal 40 residues reported a yield of only 20 mg per litre starting culture [22]. In another 
report, non-tagged full-length PCV2b capsid protein produced by bacterial expression from 
a codon-optimized construct reached about 50 mg per litre bacterial culture [24]. A patent 
for preparation of a PCV2 recombinant antigen reported the antigen content produced by 
their process to be in the range of tens of mg per litre starting culture. Fed-batch 
fermentation systems are widely used in commercial E. coli- based production systems 
and there is thus every expectation that the protocol used in this study will be scalable. 
Second, the tag-independent 1-step purification protocol can be easily adapted to 
commercial-scale production. Third, the resulting protein has a level of purity that is 
exceptional and consistent with expectations in this field. Most importantly, the PCV2d 
antigen produced in this work induced strong and specific antibody production in 
immunised animals, and these antisera show efficient neutralising effects against the 
current PCV2d strain, which is a hallmark quality of successful PCV2 vaccines.  
 
Most of the previous works have established that their candidate antigens generated by 
microbial fermentation formed VLPs that could subsequently induce PCV2-specific 
antibody responses in test animals [23-25]. It is reasonable to expect that VLPs, 
presenting structures that more closely resemble the viruses, could efficiently induce 
relevant protective antibodies. However, it has not been demonstrated empirically in test 
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animals whether non-VLP antigens could also induce such response. In our experiments, 
we demonstrated via size exclusion chromatography analysis that the PCV2d antigen from 
these constructs did not form VLPs, agreeing with recent work in characterisation of PCV2 
capsid lacking part or all of this N-terminal nuclear localisation signal [27]. Interestingly, 
despite lacking VLP structures, our antigen could induce PCV2d-neutralising antibodies in 
test animals at reasonable VN titres. From the perspective of commercial scale production, 
this could become one of the important considerations as extra steps of VLP formation, 
purification, and characterisation will be required at additional cost during vaccine 
bioprocess and regulatory approvals.    
 
One of our initial goals was to create a candidate antigen for a dual vaccine that can 
induce specific antibody responses to both PCV2d and PCV3. Unfortunately, efforts to 
generate soluble chimeric proteins by changing expression conditions, bacterial strains, or 
the amino acid composition of the linkers did not lead to successful solubilisation (see 
Methods for constructs; data not shown). Expressed at high levels, the chimeric PCV2d-
PCV3 construct could be further developed by IMAC purification under denaturing 
conditions and refolding. Indeed, our initial purification trial could generate purified full-
length chimeric PCV2d-PCV3 protein that could be used to immunise test animals. On the 
other hand, we showed that eluates during purification of the soluble fractions expressing 
this construct contained PCV3 peptides. Further optimisation, especially involving 
prevention of proteolytic degradation and more effective fractionations, could possibly 
enrich PCV3-derived peptides along with the purified soluble PCV2d antigens.  
 
In summary, this work attempted to express and purify antigens comprising capsid 
proteins of the currently circulating PCV2d virus and the novel PCV3 virus. We 
successfully produced a PCV2d antigen in a form that is highly expressed during microbial 
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fermentation and efficiently purified in a scalable 1-step chromatographic process. 
Moreover, the PCV2d-PCV3 chimera could be expressed at high levels during 
fermentation and the construct is efficiently cleaved to yield even higher amounts of 
PCV2d supplemented with PCV3-related peptides. The antigens generated from these 
novel constructs demonstrated neutralising activity that indicate a high potential for use as 
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Figure 1. Design of PCV2d and PCV2d-PCV3 constructs.   
The PCV2d construct was created by truncating N-terminal amino acids 2 – 40 from the 
full length PCV2d gene (top), while the PCV2d-PCV3 chimera construct was created by 
truncating amino acids 2 – 40 from PCV2d, and joining it by a short glycine-serine linker to 
the truncated PCV3 gene with amino acids deleted between 1 – 34 and 195-214 regions 
(bottom). Both were tagged with a C-terminal His6 tag for immunoblotting and purification. 
 
Figure 2. Initial expression of PCV2d and PCV2d-PCV3 in shake flask culture. PCV2d 
and PCV2d-PCV3 were expressed in shake flask cultures and synthesis was induced with 
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IPTG after 3h. The cells were pelleted, lysed and centrifuged to generate soluble and 
insoluble (Sol, Insol) which were analysed using Coomassie-stained SDS-PAGE (left) and 
anti-PCV2d immunoblot (right). The mobilities of the 2 protein constructs are indicated, 
and mobilities of molecular weight markers (in kDa) are shown on the left.  
 
Figure 3. Purification of PCV2d from E. coli lysates using a 1-step procedure. (A) 
PCV2d was expressed in E. coli W3110 cells under fed-batch fermentation conditions. 
After an induction period of 42 h the cells were pelleted, lysed and centrifuged as detailed 
in Materials and Methods. The lysate was applied to an SP-Sepharose-FF column pre-
equilibrated in 50 mM Tris-HCl, 0.1 mM DTT, pH 7.0, which was then washed with 5 
column volumes of the same buffer. Elution was achieved using a gradient of 0 - 1 M NaCl 
in the same buffer. Samples of the wash and elution fractions were analysed using SDS-
PAGE. A doublet of PCV2d proteins is indicated on the right. (B) Base peak intensity 
chromatogram of the PCV2d in peak fraction after an in solution digestion (DTT/IAM, 




Figure 4. The PCV2d-PCV3 chimera is cleaved to yield high levels of soluble PCV2d 
during shake flask growth in fed-batch fermentation media. PCV2d and PCV2d-PCV3 
were expressed in W3110 cells under shake flask conditions using fed-batch fermentation 
media, and synthesis was induced using IPTG. After induction periods of 3, 5 or 21 h, 
samples were centrifuged to pellet the cells, which were lysed and centrifuged to yield 
soluble and insoluble fractions (S, In). These were run on SDS-PAGE and immunoblotted 
using antibodies to PCV2d (see Materials and Methods). Mobilities of PCV2d and PCV2d-




Figure 5. Development of an extended fed-batch fermentation protocol for the 
production of soluble PCV2d from the PCV2d-PCV3 chimera. PCV2d-PCV3 was 
expressed under fed-batch fermentation conditions and samples were analysed just 
before induction with IPTG (0 h) and after periods of induction shown. Cells were lysed 
and centrifuged to generate soluble and insoluble fractions (S, In) and the fractions were 
analysed by immunoblotting using antisera to PCV2d.  
 
Figure 6. Purification and analysis of soluble PCV2d derived from the PCV2d-PCV3 
chimera. (A) The soluble fraction obtained from the 42 h induction time point shown in 
Figure 5 was applied to an SP-Sepharose-FF column, and the column was washed and 
eluted using the procedure described in Figure 3. Samples of the wash and NaCl elution 
fractions were analysed using Coomassie-stained SDS gels. (B) ESI-LC-MS 
chromatogram (base peak intensity) for IEX fraction 8 and 10 after an in-solution protease 
trypsin digestion (DTT/IAM, for 12 hours). (C) Peptide mapping of the chimera protein 
PCV2d-PCV3 including the GSGSG linker at AA196-200 from fraction 8 (left) and 10 
(right), respectively. 
 
Figure 7. Purified PCV2d does not form a high molecular mass complex. Soluble 
PCV2d, purified after expression of the PCV2d-PCV3 chimera as detailed in Figure 6, was 
subjected to size exclusion chromatography using a Superdex™ 200 Increase 10/300 GL 
column. Elution fractions were analysed by immunoblotting with PCV2d antisera, with the 
PCV2d indicated and the mobilities of molecular mass markers (in kDa) also indicated on 
the left of the blot. The column was calibrated using a group of molecular mass standards 
and the peak elution point (= retention volume) for each standard is shown by arrows with 
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the mass of the standards (in kDa) shown. The chromatogram obtained during 
chromatography of the standards is shown in the inset.  
 
Figure 8. Characterisation of antisera raised against purified PCV2d. Antisera were 
raised against purified PCV2d by immunisation of 2 rabbits, and these antisera were 
tested for cross-reaction to specific proteins. (A) Two immunoblots showing reactivity (from 
left to right) of the sera from rabbits 1 and 2 against E. coli cell lysates, containing 
approximately 1 µg PCV2d, a 1/5 dilution of the same sample containing 0.2 µg PCV2d, 
0.5 µg PCV2d-PCV3 chimera, 1/5 dilution of the same sample containing 0.1 µg PCV2d-
PCV3 chimera, 0.2 µg PCV3, and 0.8 µg of a control protein, a 28 kD single-chain 
antibody fragment (scFv). (B) Immunofluorescence of PK-15 cells mock-infected (left) or 
infected with PCV2d (strain BDH; right) detected with anti-PCV2d antibody purified from 
the rabbi antisera. Scale bar, 50 μm. 
 
Figure 9. Antisera can neutralise PCV2d infection in cell-based assay.  (A) PK-15 
cells were infected with PCV2d virus pre-treated with different dilutions of pre- or post-
immunisation sera from Rabbit 2 before imaged by immunofluorescence at 48 h post-
infection. Cells infected by PCV2d showed green fluorescence. Nuclei were stained with 
DAPI. Figures are from a representative set of three independent experiments. Numbers 
below each panel (N), quantified by the high-content system detailed in Methods,  
indicated PCV2d-infected cells. (B) Virus neutralising titres in pre- and post-immunisation 
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